In recent months, the biotech and biopharma industries have been struggling with layoffs and dropping stocks. However, some companies are still experiencing success. Sanofi, AstraZeneca, Avillion and Diadem recently announced positive clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.
Bruised and battered by its failings with the controversial Alzheimer’s drug Aduhelm, Biogen is looking to right the ship with a new helmsman. The company is on the hunt for a new chief executive officer.
Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.
Alzheon posted positive results from the company’s Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders such as Alzheimer’s disease.
With $29 million in the company’s pocket, biotech Libra Therapeutics launched to take on neurodegenerative disease, with three pre-clinical programs ready to roll.
Merck & Co. plunked down $576 million to acquire San Diego-based Calporta Therapeutics Inc. to gain access to preclinical TRPML1 agonists that are seen as potential treatments for neurodegenerative disorders such as Alzheimer’s and Parkinson’s.
Researchers with Cortexyme published research in the journal Science Advances describing the role of Porphyromonas gingivalis, a bacteria that causes gingivitis, to Alzheimer’s disease.
Scientists at DZNE, HIH, and the University Hospital Tuebingen identified a protein in blood that can precisely track Alzheimer’s disease progression before the first symptoms appear.
